Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesProgress in tailoring adjuvant endocrine therapy for postmenopausal women with early breast cancer
Current Opinion in Oncology, 10/12/09
Bedard PL et al. – There are no robust clinically available tools that can be used to reliably identify patients that are likely to be selectively responsive to an aromatase inhibitor over tamoxifen alone. The decision to use an aromatase inhibitor in clinical practice should be primarily guided by consideration of recurrence risk and contraindications to tamoxifen.
Related Articles
Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers
Journal of Clinical Oncology, 10/29/09
Relevance Score: 74%
Advanced Breast Cancer and Breast Cancer Mortality in Randomized Controlled Trials on Mammography Screening
Journal of Clinical Oncology, 11/09/09
Relevance Score: 72%
Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients
Breast Cancer Research and Treatment, 10/27/09
Relevance Score: 72%
Underweight and breast cancer recurrence and death: A report from the Korean breast cancer society
Journal of Clinical Oncology, 10/08/09
Relevance Score: 72%
Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast cancer: a nested case-control study
Cancer Epidemiology, Biomarkers & Prevention, 10/01/09
Relevance Score: 72%
Today in Breast...keeping you current
Receive free subspecialty "5-minute updates" via email
Flat epithelial atypia is a common subtype of B3 breast lesions and associated with noninvasive cancer but not with invasive cancer in final excision histology
Human Pathology, 12/19/09
Extracellular Signal–Regulated Kinase Signaling Pathway Regulates Breast Cancer Cell Migration by Maintaining slug Expression
Cancer Research, 12/18/09
The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: A phase II study
International Journal of Cancer, 12/18/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: A phase II study
International Journal of Cancer, 12/18/09
Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: Results from a randomized phase II study
Palliative Medicine, 12/18/09
A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: An Eastern Cooperative Oncology Group Trial
Breast Cancer Research and Treatment, 12/17/09
Sponsor
Article Search
Sponsor
Sponsor